Results 111 to 120 of about 261,869 (302)

Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real‐World Data Utilization

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical trials with pragmatic elements can capture diverse patient populations, enable efficient follow‐up, and reflect routine clinical practices; yet there is limited understanding of their design features, characteristics, and use of real‐world data (RWD). Based on a targeted search of PubMed/EMBASE (Jan‐2016 to Jul‐2024), a review was conducted to
Le Su, Lei Chen, Seema Betigeri, Nancy Dreyer, Helga Gardarsdottir, Rachele Hendricks‐Sturrup, Mehmet Burcu   +6 more
wiley   +1 more source

Anti-influenza antibody level after vaccination in north of Iran [PDF]

, 2009
Objective:Influenza is a highly transmitted disease and about 10% of the world's population is affected by this disease annually. The aim of this research was to study the variation of serum antibody levels among subjects who had already been vaccinated ...
Abbasi, A., Mansourian, A.R., Moradi, A., Rajaei, S.   +3 more
core  

Inactivated Influenza Vaccine Efficacy: Diminished Antigenicity of Split-Product Vaccines in Mice [PDF]

, 1974
David W. Barry, Eldridge Staton, Ronald E. Mayner   +2 more
openalex   +1 more source

Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classification

ESC Heart Failure, EarlyView.
Abstract Clinical endpoint classification (CEC)—that is, evaluation of clinical events using pre‐defined criteria—is commonly conducted in clinical trial operations to ensure systematic and consistent assessment of endpoints needed to assess the intervention's safety and efficacy.
Veraprapas Kittipibul, Harriette G.C. Van Spall, William Schuyler Jones, Marat Fudim, Robert J. Mentz, Kevin Anstrom, Bertram Pitt, Patrice Desvigne‐Nickens, Jerome L. Fleg, Camilla Hage, Stefan James, Claes Held, Lars Lund, Adam DeVore   +13 more
wiley   +1 more source

Neuraminidase and resistance to vaccination with live influenza A2 Hong Kong vaccines [PDF]

, 1971
A. N. Slepushkin, G. C. Schild, A. S. Beare, S Chinn, D. A. J. Tyrrell   +4 more
openalex   +1 more source

VACCINES FOR INFLUENZA [PDF]

BMJ, 1918
openaire   +3 more sources

Socioeconomic determinants of vaccination against pneumococcus in 763 945 patients with heart failure

ESC Heart Failure, EarlyView.
Respiratory infections heighten risks for heart failure (HF) patients, yet 2020 data from France show low vaccination rates: 12.6% for pneumococcus and 63.1% for influenza. Using logistic regression on 763,945 HF patients, older age, female sex, and social deprivation were associated with lower pneumococcus vaccination, despite frequent healthcare ...
F. Roubille, B. Wyplosz, J. Fernandes, B. Grenier, F. Raguideau, E. Blanc, G. Goussiaume   +6 more
wiley   +1 more source

Antibody Responses in Serum and Nasal Secretions According to Age of Recipient and Method of Administration of A2/Hong Kong/68 Inactivated Influenza Virus Vaccine [PDF]

, 1970
Robert V. Fulk, David S. Fedson, Margret A. Huber, James R. Fitzpatrick, J. A. Kasel   +4 more
openalex   +1 more source

A Practical Approach to Implementing ICH Q14: Tools for Analytical Quality by Design in Capillary Electrophoresis Method Development

ELECTROPHORESIS, EarlyView.
ABSTRACT The ICH Q14 guideline introduces a structured framework for analytical method development based on Analytical Quality by Design (AQbD) principles, aiming to ensure robust, reliable, and fit‐for‐purpose methods throughout the product lifecycle.
Ewoud van Tricht, Cari E. Sänger ‐ van de Griend   +1 more
wiley   +1 more source

Chromatographic isolation of the hemagglutinin polypeptides from influenza virus vaccine and determination of their amino-terminal sequences. [PDF]

, 1976
Doris J. Bucher, S S Li, J. Michael Kehoe, Edwin D. Kilbourne   +3 more
openalex   +1 more source